Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(30%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
2
20%
Ph phase_1
5
50%
Ph phase_3
3
30%

Phase Distribution

5

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
3(30.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(3)
Other(2)

Detailed Status

Completed3
unknown2
Active, not recruiting2
Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (50.0%)
Phase 22 (20.0%)
Phase 33 (30.0%)

Trials by Status

recruiting110%
completed330%
unknown220%
active_not_recruiting220%
not_yet_recruiting220%

Recent Activity

3 active trials
Showing 5 of 10
recruitingphase_1

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158
completedphase_3

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

NCT04221945
active_not_recruitingphase_1

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

NCT05566574
active_not_recruitingphase_3

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
not_yet_recruitingphase_3

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

NCT06333821
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03317158Phase 1

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Recruiting
NCT04221945Phase 3

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Completed
NCT05566574Phase 1

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Active Not Recruiting
NCT04634877Phase 3

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Active Not Recruiting
NCT06333821Phase 3

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Not Yet Recruiting
NCT05799469Phase 2

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

Not Yet Recruiting
NCT02748200Phase 1

External Beam Radiotherapy for Muscle Invasive Bladder Cancer

Completed
NCT05105672Phase 2

A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer

Unknown
NCT03308604Phase 1

AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy

Unknown
NCT00899054Phase 1

Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer

Completed

All 10 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
10